Recombinant AAV vectors provide non-integrating, long-term expression of RNA-targeting payloads in the CNS.[@highland2024] Recent advances in capsid engineering have improved CNS tropism and reduced immunogenicity.[@klein2023]
Key advantages:
Long-term expression (years) from single administration
Broad neuronal and glial transduction
Proven clinical safety in other CNS indications (SMA, CLN2)[@sah2023]
Ability to target specific brain regions via stereotactic injection
RNA-Targeting Modalities
Antisense Oligonucleotides (ASOs): Single-stranded DNA analogs that bind complementary RNA to modulate splicing or reduce translation
RNAi (shRNA/siRNA): Double-stranded RNA molecules that trigger sequence-specific mRNA degradation
RNA Aptamers: Structured RNAs that bind protein targets to modulate their function
Therapeutic Rationale
In neurodegeneration, specific genetic drivers can be targeted to reduce toxic protein expression:[@finkel2024]
AAV delivery addresses the key limitation of traditional ASO approaches (requires repeated intrathecal dosing) while enabling cell-type specific targeting.[@miller2023][@bennett2022]
Scoring (10-Dimension Rubric)
| Dimension | Score | Rationale | |-----------|-------|-----------| | Novelty | 8 | First-in-class AAV+RNA targeting combination; only now becoming technically feasible | | Mechanistic Rationale | 9 | Strong genetic validation; reducing toxic protein levels is well-established therapeutic strategy | | Addresses Root Cause | 8 | Directly reduces expression of disease-driving proteins | | Delivery Feasibility | 6 | AAV delivery proven but requires stereotactic injection; CNS selectivity still developing | | Safety Plausibility | 7 | AAV platform has good safety profile; off-target effects of RNA targeting need monitoring | | Combinability | 8 | Combines well with small molecule approaches, other gene therapies | | Biomarker Availability | 7 | Target protein levels in CSF; sequencing to confirm on-target reduction | | De-risking Path | 7 | Can use mouse models; iPSC-derived [neurons](/entities/neurons) for human validation | | Multi-disease Potential | 9 | Platform applicable across AD, PD, ALS, FTD with minimal modification | | Patient Impact | 8 | Potentially disease-modifying; single administration could provide years of benefit |
Total: 77/100
Target Selection by Disease
Alzheimer's Disease
| Target | Rationale | Approach | |--------|-----------|----------| | APP | Direct cause of Aβ production | ASO to reduce APP translation | | PSEN1/2 | [Gamma-secretase](/entities/gamma-secretase) catalytic subunit | ASO to reduce mutant expression | | APOE4 | Major genetic risk factor | RNA aptamer to block ApoE4 aggregation |
Parkinson's Disease
| Target | Rationale | Approach | |--------|-----------|----------| | SNCA | [Alpha-synuclein](/proteins/alpha-synuclein) multiplication is causal | RNAi to reduce expression | | LRRK2 | Most common genetic cause (G2019S) | ASO to reduce mutant kinase | | GBA1 | Strong genetic risk factor | Increase expression via UTR modulation |
ALS/FTD
| Target | Rationale | Approach | |--------|-----------|----------| | C9orf72 | 40% familial ALS, 25% FTD | ASO to reduce toxic DPRs | | SOD1 | 20% familial ALS | RNAi to reduce mutant protein | | FUS | 5% familial ALS | ASO to reduce mutant expression | | GRN | Causes progranulin deficiency in FTD | Increase expression via RNA targeting |
Frontotemporal Dementia
| Target | Rationale | Approach | |--------|-----------|----------| | MAPT | Tau mutations cause FTD | ASO to reduce tau isoforms | | TMEM106B | Major risk factor | Modulate expression | | GRN | Progranulin haploinsufficiency | Increase expression |
Development Pathway
Phase 1: Target Validation (Months 1-18)
Validate target knockdown in patient-derived iPSC neurons
Confirm phenotypic improvement in disease models
Optimize AAV serotype for target brain region
Establish PK/PD relationship in non-human primates
Phase 2: IND-Enabling Studies (Months 12-30)
GMP vector production and release testing
IND-enabling toxicology in rodents and NHPs
Develop CSF biomarker assay for target engagement
Design clinical dosing regimen
Phase 3: Clinical Development (Months 24-48)
Phase 1 safety in small patient cohort[@stoops2023]
Dose-escalation with biomarker readouts
Registrational trial design for specific indication
Companion diagnostic development
Combination Therapy Opportunities
Synergistic Targets
+ Small Molecule Modulators: Combine AAV-RNA targeting with small molecule pathway modulators for enhanced effect
+ Antibody Therapies: Complement intracellular targeting with extracellular antibody approaches
+ Cell Therapy: Combine with iPSC-derived cell delivery
+[TFEB](/entities/tfeb) Activators: Enhance clearance of existing protein aggregates while reducing new production
Preclinical Combination Data
AAV-ASO + TFEB agonist: Synergistic reduction of protein aggregates in models[@keeler2022]
RNAi targeting + antibody: Enhanced clearance via dual mechanism
Actionable Next Steps
Lab Experiments
Vector Engineering: Screen AAV capsids (AAV9, AAV-PHP.B, novel variants) for optimal CNS transduction and minimal off-target delivery
Promoter Selection: Test neuronal (Synapsin, CamKII), astrocytic (GFAP), and microglial (CD68) promoters for cell-type specificity
Payload Optimization: Compare ASO, shRNA, and siRNA for knock-down efficiency and duration
Dose-Response: Establish minimal effective dose in mouse models
Biodistribution: Characterize vector distribution post-injection via imaging and qPCR
Wave Life Sciences: Pivotal ASO platform with stereochemistry for enhanced tissue exposure
NeuBase Therapeutics: PATRIOT platform for ASO delivery
Implementation Roadmap
Phase 1: Target Validation ($2.5-4M, Months 1-18)
Vector engineering and screening: $800K
In vitro validation (iPSC neurons): $600K
In vivo proof-of-concept (mouse models): $700K
Pharmacokinetics/biodistribution: $400K
IND-enabling studies start: $500K
Milestone: Demonstrate >70% target knock-down in relevant models
Phase 2: IND-Enabling ($5-8M, Months 12-30)
GMP manufacturing: $2M
GLP toxicology (rodent + NHP): $2.5M
Biomarker assay development: $500K
Regulatory interactions: $300K
Clinical protocol finalization: $700K
Milestone: IND clearance
Phase 3: Clinical Development ($25-40M, Months 24-54)
Phase 1 trial: $5-8M
Phase 2 trial: $10-15M
Phase 3 trial: $10-17M
Milestone: Regulatory approval or partnership exit
Total Program Cost: $33-52M over 54 months
Risk Assessment
| Risk | Likelihood | Impact | Mitigation | |------|------------|--------|------------| | Immunogenicity against AAV | Medium | High | Pre-screen for neutralizing antibodies; use novel capsids | | Off-target RNA effects | Low | Medium | Extensive bioinformatic analysis; chemical modifications | | Delivery to non-target regions | Medium | Medium | Advanced imaging for distribution; promoter optimization | | Regulatory complexity | Medium | Medium | Early FDA engagement; rare disease pathway if applicable |
Go/No-Go Decision Points
Month 6: Continue if >50% knock-down in vitro
Month 12: Continue if proof-of-concept in vivo with acceptable safety
Month 24: Continue if IND-enabling studies successful
Month 36: Continue if Phase 1 shows acceptable safety + biomarker signal
Cross-Linking
[TREM2](/proteins/trem2) - Related microglial target
C9orf72 - Target for ALS/FTD
SNCA - Target for PD
LRRK2 - Target for PD
APP - Target for AD
MAPT - Target for FTD
GRN - Target for FTD
SOD1 - Target for ALS
Alpha-Synuclein - Pathogenic protein in PD
[Tau Protein](/proteins/tau) - Pathogenic protein in AD/FTD